Table 1 Baseline characteristics of patients with NPC treated with or without Nimotuzumab
Characteristic | Nimotuzumab Arm N = 184(%) | No Nimotuzumab Arm N = 546(%) | P value |
|---|---|---|---|
Gender | 0.704 | ||
Female | 37(20.11) | 117(21.43) | |
Male | 147(79.89) | 429(78.57) | |
Age, Mean (SD) | 43.92 (10.53) | 44.1 2(10.62) | 0.822 |
<44 | 95(51.63) | 253(46.34) | |
≥ 44 | 89(48.37) | 293(53.66) | |
WHO pathology | 0.436 | ||
I | 3(1.6) | 11(2.0) | |
II | 8(4.3) | 14(2.6) | |
III | 173(94.1) | 521(95.4) | |
T classification | 0.966 | ||
T1 | 5(2.72) | 17(3.11) | |
T2 | 16(8.70) | 42(7.69) | |
T3 | 107(58.16) | 317(58.06) | |
T4 | 56(30.42) | 170(31.14) | |
N classification | 0.972 | ||
No | 19(10.33) | 57(10.44) | |
N1 | 75(40.76) | 230(42.13) | |
N2 | 73(39.67) | 214(39.19) | |
N3 | 17(9.24) | 45(8.24) | |
Clinical stage | 0.937 | ||
III | 116(63.04) | 346(63.37) | |
IVa | 51(27.72) | 155(28.39) | |
IVb | 17(9.24) | 45(8.24) | |
Chemotherapy | 0.684 | ||
Concurrent | 61(33.15) | 190(34.80) | |
Induction + concurrent | 123(66.85) | 356(65.20) |